Acutaas Chemicals Reports Consolidated and Standalone Financial Results for First Quarter Ended June 30, 2026
Acutaas Chemicals Ltd, formerly Ami Organics Limited, has released its Unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. The results include details of the company and its subsidiaries, joint venture, and step down companies.The consolidated results reflect the performance across several entities, including Acutaas Chemicals Electrolytes Private Limited, Acutaas Advance Material Limited, Baba Fine Chemicals (Partnership Firm), Ami Onco-Theronostics, LLC, Enchem Ami Organics Private Limited, and Indichem Inc. The company operates in a single segment, specializing in the custom synthesis and manufacturing of Specialty Chemicals for Pharmaceuticals API and related industries.
Consolidated Unaudited Financial Results Summary
For the quarter ended June 30, 2026, the Group reported Total Income of 33,147.61 lakhs, against a Revenue from operations of 32,967.48 lakhs. The company recorded Total expenses of 22,756.60 lakhs.The Consolidated Unaudited Financial Results for the quarter are presented in lakhs:
| Particulars | Quarter Ended June 30, 2026 (Unaudited) | March 31, 2026 (Unaudited) | June 30, 2025 (Unaudited) | March 31, 2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 32,967.48 | 43,275.05 | 20,723.72 | 133,936.68 |
| Other income | 180.13 | 111,110 | 1,593.77 | 4,158.52 |
| Total income | 33,147.61 | 44,386.15 | 22,317.49 | 138,095.20 |
| Total expenses | 22,756.60 | 26,005.98 | 16,509.92 | 89,822.63 |
The results also include a summary of key financial metrics:
| Particulars (Consolidated) | Quarter Ended June 30, 2026 | March 31, 2026 | June 30, 2025 | March 31, 2026 |
|---|---|---|---|---|
| Profit before tax | 10,391.01 | 18,380.17 | 580757 | 48,272.57 |
| Total tax expense | 2,891.74 | 4,951.80 | 1,406.52 | 12,635.64 |
| Profit attributable to Owners of the company (Non-controlling interest) | 7,426.01 | 13,176.08 | 4,429.34 | 35,625.53 |
Standalone Unaudited Financial Results Summary
The standalone results of Acutaas Chemicals Ltd for the quarter ended June 30, 2026, showed Total Income of 32,688.52 lakhs against Revenue from operations of 32,240.92 lakhs. The total expenses amounted to 22,287.02 lakhs.The Standalone Unaudited Financial Results for the quarter are detailed below:
| Particulars | Quarter Ended June 30, 2026 (Unaudited) | March 31, 2026 (Unaudited) | June 30, 2025 (Unaudited) | March 31, 2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 32,240.92 | 42,177.23 | 20,597.09 | 132,379.22 |
| Other income | 447.60 | 1,454.59 | 1,602.01 | 4,587.83 |
| Total Income | 32,688.52 | 43,631.82 | 22,199.10 | 136,967.05 |
| Total expenses | 22,287.02 | 25,045.73 | 16,306.40 | 87,689.66 |
Operational and Corporate Updates
During the reporting quarter, a subsidiary of the Company, Acutaas Chemicals Electrolytes Private Limited (ACEPL), underwent a preferential issue of equity shares to A.R.Z Pharma Ltd. This event caused the Company’s shareholding in ACEPL to change from 100% to 90%, effectively changing its status from a wholly owned subsidiary to a subsidiary.Furthermore, during the quarter, Central Goods & Service Tax and Central Excise (CGST & CE), Anti-Evasion Department initiated inspection/search proceedings at the Company's registered office and manufacturing facility in Surat, Gujarat, concluding the process on June 23, 2026. Management has stated that it does not anticipate any material impact from this event on the financial results or cash flows of the company.
ACUTAAS Stock Price Movement
Acutaas Chemicals Limited stock is shedding ground as of 12:43 PM, trading down 3.61% to ₹3334.2, having fallen by ₹124.90 from the previous close. The equity has seen significant intraday movement, fluctuating between a low of ₹3250 and a high of ₹3457.1 amidst 257,771 shares trading today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.